Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553473 | 0.80 | PPARG (1.00) | PPARAPPARG | |
| SCHEMBL20553475 | 0.80 | PPARG (1.00) | PPARAPPARG | |
| SCHEMBL8935901 | 0.78 | PPARA (0.51) | PPARAPPARG | |
| SCHEMBL1814149 | 0.78 | PPARA (0.51) | PPARAPPARG | |
| SCHEMBL5063037 | 0.78 | PPARA (0.51) | PPARAPPARG | |
| SCHEMBL10877367 | 0.76 | PPARA (0.56) | PPARAPPARG | |
| SCHEMBL15446243 | 0.74 | SRR (0.71) | PPARAPPARG | |
| SCHEMBL29406517 | 0.74 | PPARA (0.68) | PPARAPPARG | |
| SCHEMBL28236550 | 0.73 | PPARA (0.80) | PPARAPPARG | |
| SCHEMBL5175856 | 0.73 | PPARA (0.44) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663113-A4 | SUBSTITUTED SULFONAMIDES | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
| EP-1663113-A2 | SUBSTITUTED SULFONAMIDES | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005027837-A2 | SUBSTITUTED SULFONAMIDES | MERCK & CO., INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105914-A1 | Substituted sulfonamides | CNR2, CNR1, FAAH | PPARA 711/4885PPARG 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.